Breaking News, Collaborations & Alliances

Innovest Global Launches Biotech Division

With the acquisition of a 20% interest in StemVax Therapeutics, who is currently developing a cancer vaccine therapy

Innovest Global launched its anticipated Biotechnology & Health Services Division today with the acquisition of a twenty percent interest in StemVax Therapeutics, a Translational Biotechnology Company that is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors. StemVax Glioblast (SVX-GB) is a cancer vaccine, which is a medication that stimulates or restores the immune system’s ability to fight an existing cancer by strengtheni...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters